Related Experiment Video
Updated: Mar 21, 2026
Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
Emerging therapies for mitochondrial disorders
Helen Nightingale1, Gerald Pfeffer2, David Bargiela1
1Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.
Abstract:
Mitochondrial disorders are a diverse group of debilitating conditions resulting from nuclear and mitochondrial DNA mutations that affect multiple organs, often including the central and peripheral nervous system. Despite major advances in our understanding of the molecular mechanisms, effective treatments have not been forthcoming. For over five decades patients have been treated with different vitamins, co-factors and nutritional supplements, but with no proven benefit. There is therefore a clear need for a new approach. Several new strategies have been proposed acting at the molecular or cellular level. Whilst many show promise in vitro, the clinical potential of some is questionable. Here we critically appraise the most promising preclinical developments, placing the greatest emphasis on diseases caused by mitochondrial DNA mutations. With new animal and cellular models, longitudinal deep phenotyping in large patient cohorts, and growing interest from the pharmaceutical industry, the field is poised to make a breakthrough.
Insights
Mitochondrial disorders, caused by DNA mutations, lack effective treatments despite decades of supplements. Promising new preclinical strategies offer hope for breakthroughs in treating these debilitating conditions.
Area of Science:
- Genetics and Molecular Biology
- Neuroscience
- Biochemistry
Background:
- Mitochondrial disorders stem from DNA mutations, impacting multiple organs, notably the nervous system.
- Current treatments, including vitamins and supplements, have shown no proven benefit for over 50 years.
- A significant unmet need exists for novel therapeutic strategies.
Purpose of the Study:
- To critically evaluate promising preclinical developments for mitochondrial disorders.
- To focus on novel strategies for diseases caused by mitochondrial DNA mutations.
- To assess the clinical potential of emerging molecular and cellular therapies.
Main Methods:
- Review of preclinical research on novel therapeutic strategies.
- Emphasis on in vitro and animal models.
- Analysis of data from deep phenotyping in patient cohorts.
Main Results:
- Many proposed strategies show promise in vitro, but clinical efficacy remains uncertain.
- Preclinical developments are advancing with new models and patient data.
- Growing pharmaceutical interest indicates a potential shift in treatment development.
Conclusions:
- Existing treatments for mitochondrial disorders are ineffective.
- New preclinical strategies are emerging, with a focus on mitochondrial DNA mutation-related diseases.
- The field is nearing a breakthrough due to improved models, patient data, and industry investment.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:45Mitochondrial Membranes
01:39Mitochondrial Precursor Proteins
Most of the mitochondrial...
02:59Animal Mitochondrial Genetics
01:37Mitochondria